Imagine building a tiny, working version of a human heart without using any glue or needles. By using magnets and sound waves to float cells in microgravity, researchers can assemble complex tissues that look and act like real organs. This allows them to study how hearts age and test new medicines more accurately than ever before.
Current 3D bioprinting often relies on scaffolds or nozzles that can damage cells or limit the complexity of the tissue. This makes it difficult to create realistic heart models for testing anti-ageing drugs.
A bioprinting platform combining magnetic and acoustic levitation. It includes a refined mathematical model to control how cell spheroids are shaped into tissue constructs.
If you are a drug discovery firm dealing with inaccurate heart-cell models for ageing research — this project developed a multi-levitation bioprinting platform that creates realistic cardiac 3D models to test the efficacy of anti-inflammatory and anti-oxidative drugs.
If you are a spaceflight company dealing with the health risks of deep space manned missions — this project developed a compact, automated bioprinter for space that studies how cosmic radiation and microgravity affect human tissues.
If you are a biotech SME dealing with the limitations of scaffold-based tissue engineering — this project developed a scaffold-free and nozzle-free bioassembly method that allows for complex geometries with voids and tunnels.
Based on available project data, there is no information regarding the cost or pricing of the device.
The project focuses on developing a compact, automated, and user-friendly device for space and Earth, but specific industrial scaling metrics are not provided in the data.
Based on available project data, the IP and licensing terms are not specified; the project is currently in the development and reporting phase.
The device is designed to be automated and user-friendly, specifically aimed at creating 3D in vitro models that replace or improve upon standard organoids.
The project period runs from 2023-04-01 to 2028-03-31, suggesting the technology is still in the development and validation phase.
The consortium is well-balanced for technology transfer, featuring a 50% industry ratio with 4 industrial partners, including 3 SMEs. Led by Universiteit Maastricht, the 8 partners across 7 countries combine academic research with commercial agility, increasing the likelihood of the technology moving from a lab setting to a business application.
Contact the research office at Universiteit Maastricht
Contact us to explore licensing opportunities for multi-levitation bioprinting.
